# A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

> **NCT07540897** · PHASE3 · RECRUITING · sponsor: **Alkermes, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Narcolepsy Type 1

## Interventions

- **DRUG:** ALKS 2680 Dose 1
- **DRUG:** ALKS 2680 Dose 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07540897
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-06
- **Final completion:** 2027-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07540897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07540897, "A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07540897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*